ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Surveillance of invasive pneumococcal disease in Germany: surge in PCV13 serotypes and new challenges, 2017 to 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDPneumococcal vaccination has been recommended in Germany for adults aged ≥ 60 years (1998) and children aged < 2 years (2006), resulting in a reduction of pneumococcal disease incidence in vaccinated children and unvaccinated individuals through herd protection.AIMWe aimed to investigate serotype distribution of invasive pneumococcal disease (IPD) among children and adults in 2017-2024.METHODSWe analysed data of an ongoing nationwide surveillance of IPD. All isolates were serotyped by Neufeld's Quellung reaction.RESULTSIn total, 24,122 IPD isolates were analysed by the German Reference Laboratory for Streptococci. Over the study period, case numbers were lower during the COVID-19 pandemic and increased afterwards with higher proportion of pneumococcal conjugate vaccine (PCV)13 serotypes. Serotypes 22F and 33F, included in PCV15 and PCV20, showed only minor variations, whereas PCV20 unique serotypes were less frequently observed in 2022-2024. Serotype 3 persisted in IPD across all age groups, while serotype 4 disappeared in children and adolescents, but increased in adults, most prominently in 18-49-year-olds. Serotype 38 steeply increased in 2023/24, among children aged < 2 years and older adults.CONCLUSIONThe concerning increase of PCV13 serotype IPD in Germany might be related to low vaccination uptake, resulting in inefficient herd protection. The dominance of serotype 3 and the rise of serotype 4 among adults highlight the importance of direct protection and support the current national vaccination recommendation for adults aged ≥ 60 years. The increase in serotype 38 IPD among young children and older adults might indicate a replacement phenomenon, highlighting the importance of IPD serotype surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.